F
Françoise Berger
Researcher at Claude Bernard University Lyon 1
Publications - 183
Citations - 13235
Françoise Berger is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Lymphoma & Mantle cell lymphoma. The author has an hindex of 61, co-authored 182 publications receiving 12253 citations.
Papers
More filters
Journal ArticleDOI
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
Kerry J. Savage,Stefano Monti,Jeffery L. Kutok,Giorgio Cattoretti,Donna Neuberg,Laurence de Leval,Paul J. Kurtin,Paola Dal Cin,Christine Ladd,Friedrich Feuerhake,Ricardo C.T. Aguiar,Sigui Li,Gilles Salles,Françoise Berger,Wen Jing,Geraldine S. Pinkus,Thomas M. Habermann,Riccardo Dalla-Favera,Nancy L. Harris,Jon C. Aster,Todd R. Golub,Margaret A. Shipp +21 more
TL;DR: A molecular link between MLBCL and cHL and a shared survival pathway is identified and a classifier of these diseases is developed.
Journal ArticleDOI
Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
Andrés J.M. Ferreri,Jean-Yves Blay,Michele Reni,Felice Pasini,Michele Spina,Achille Ambrosetti,A. Calderoni,Andrea Rossi,V. Vavassori,Annarita Conconi,Liliana Devizzi,Françoise Berger,Maurilio Ponzoni,Bettina Borisch,Marianne Tinguely,Michele Cerati,Mario Milani,Enrico Orvieto,JG Sanchez,Christine Chevreau,Stefania Dell'Oro,Emanuele Zucca,Franco Cavalli +22 more
TL;DR: Age, PS, LDH serum level, CSF protein concentration, and involvement of deep structures of the brain were independent predictors of survival and a prognostic score including these five parameters seems advisable in distinguishing different risk groups in PCNSL patients.
Journal ArticleDOI
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed
Catherine Thieblemont,Françoise Berger,Charles Dumontet,Isabelle Moullet,Fadhela Bouafia,Pascale Felman,Gilles Salles,Bertrand Coiffier +7 more
TL;DR: MALT lymphoma is an indolent disease but presents as a disseminated disease in one-third of the cases at diagnosis, and the dissemination does not change the outcome of the patients.
Journal ArticleDOI
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Javeed Iqbal,George E. Wright,Chao Wang,Andreas Rosenwald,Randy D. Gascoyne,Dennis D. Weisenburger,Timothy C. Greiner,Lynette M. Smith,Shuangping Guo,Ryan A. Wilcox,Bin Tean Teh,Soon Thye Lim,Soon Yong Tan,Lisa M. Rimsza,Elaine S. Jaffe,Elias Campo,Antonio Martinez,Jan Delabie,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,German Ott,Eva Geissinger,Philippe Gaulard,Pier Paolo Piccaluga,Stefano Pileri,Wing Yan Au,Shigeo Nakamura,Masao Seto,Françoise Berger,Laurence de Leval,Joseph M. Connors,James O. Armitage,Julie M. Vose,Wing C. Chan,Louis M. Staudt +35 more
TL;DR: Gene-expression profiles, immunohistochemistry, and IDH2 mutation analysis in reclassified cases supported the validity of the reclassification of PTCL-NOS cases, and high expression of several signatures associated with the tumor microenvironment was significantly associated with outcome.
Journal ArticleDOI
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Fermé,Houchingue Eghbali,J.H. Meerwaldt,Chantal Rieux,Jacques Bosq,Françoise Berger,Theodore Girinsky,Pauline Brice,Mars B. van't Veer,Jan Walewski,Pierre Lederlin,Umberto Tirelli,Patrice Carde,Eric Van Den Neste,Emmanuel Gyan,Mathieu Monconduit,Marine Diviné,John M. M. Raemaekers,Gilles Salles,Evert M. Noordijk,Geert Jan Creemers,Jean Gabarre,Anton Hagenbeek,Oumedaly Reman,Michel Blanc,José Thomas,B. Vie,Johanna Kluin-Nelemans,Fernando Viseu,Joke W. Baars,Philip Poortmans,Pieternella J. Lugtenburg,Christian Carrie,Jérôme Jaubert,Michel Henry-Amar +34 more
TL;DR: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features and in patients with unfavorable features, four courses of chemotherapyplus involved- field radiotherapy ought to be thestandard treatment.